芳香化酶抑制剂与他莫昔芬在绝经后乳腺癌女性中的心脏毒性:随机对照试验的系统综述与荟萃分析
该系统综述与荟萃分析纳入19项随机对照试验(n=62345),比较辅助或延长辅助治疗中芳香化酶抑制剂(AIs)与他莫昔芬的心血管安全性。辅助治疗中AIs较他莫昔芬心血管事件风险升高19%(RR 1.19,95%CI 1.07-1.34),延长辅助治疗中AIs与安慰剂相比风险未增加(RR 1.01,95%CI 0.85-1.20)。作者认为AIs相对他莫昔芬的心血管风险增加可能源于他莫昔芬的心脏保护作用。
要点
- 辅助治疗中AIs较他莫昔芬心血管事件风险升高19%(RR 1.19,95%CI 1.07-1.34)。
- 延长辅助治疗中AIs与安慰剂相比心血管风险未增加(RR 1.01,95%CI 0.85-1.20)。
- 辅助治疗中他莫昔芬较安慰剂或无治疗心血管风险降低33%(RR 0.67,95%CI 0.45-0.98)。
核心结论
- AIs相对他莫昔芬的心血管事件风险增加可能是他莫昔芬心脏保护作用的结果。
- 作者认为在评估AIs治疗乳腺癌的获益与风险时应考虑这一新证据。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase(OVID)、Cochrane CENTRAL、WHO国际临床试验注册平台和ClinicalTrials.gov自建库至2016年6月。
- 纳入19项随机对照试验,共n=62345例,比较辅助或延长辅助治疗中AIs与他莫昔芬、AIs与安慰剂或无治疗、或他莫昔芬与安慰剂或无治疗的心血管和脑血管安全性。
- 采用DerSimonian and Laird随机效应模型合并相对风险(RR),并按随机对照试验设计分层分析。
主要发现
- 辅助治疗中AIs较他莫昔芬心血管事件风险升高19%(RR 1.19,95%CI 1.07-1.34)。
- 延长辅助治疗中AIs较安慰剂心血管事件风险未增加(RR 1.01,95%CI 0.85-1.20)。
- 辅助治疗中他莫昔芬较安慰剂或无治疗心血管事件风险降低33%(RR 0.67,95%CI 0.45-0.98)。
- 延长辅助治疗中他莫昔芬较安慰剂的随机对照试验结果不确定,但提示小幅保护作用(RR 0.91,95%CI 0.77-1.07)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Aromatase inhibitors (AIs) have been associated with cardiovascular disease in adjuvant randomized controlled trials (RCTs) comparing these drugs to tamoxifen. However, it is unclear whether this risk is real or due to cardioprotective effects of tamoxifen. To address this question, we conducted a systematic review and meta-analysis of all RCTs of AIs and tamoxifen in adjuvant and extended adjuvant setting. PATIENTS AND METHODS: We searched PubMed, Embase (OVID), Cochrane CENTRAL, WHO International Clinical Trials Registry Platform, and ClinicalTrials.gov from inception to June 2016 for all RCTs comparing cardiovascular and cerebrovascular safety of AIs to tamoxifen, AIs to placebo or no-treatment, or tamoxifen to placebo or no-treatment in the adjuvant or extended adjuvant setting. Relative risks (RRs) were pooled using DerSimonian and Laird random-effects models with analyses stratified by RCT design. RESULTS: A total of 19 RCTs were included in the meta-analysis (n = 62 345). In the adjuvant setting, AIs were associated with a 19% (RR: 1.19, 95% confidence interval [CI]: 1.07-1.34) increased risk of cardiovascular events compared with tamoxifen. AIs were not associated with an increased risk compared with placebo in the extended-adjuvant setting (RR: 1.01, 95% CI: 0.85-1.20). In the adjuvant setting, tamoxifen was associated with a 33% (RR: 0.67, 95% CI: 0.45-0.98) decreased risk compared with placebo or no-treatment. The results from extended adjuvant RCTs comparing tamoxifen to placebo were inconclusive but suggestive of a small protective effect (RR: 0.91, 95% CI: 0.77-1.07). CONCLUSIONS: The increased risk of cardiovascular events with AIs relative to tamoxifen is likely the result of cardioprotective effects of the latter. This new evidence should be considered when assessing the benefits and risks of AIs in the treatment of breast cancer.
引用
- Khosrow-Khavar F, Filion KB, Al-Qurashi S, et al. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2017. PMID: 27998966. doi:10.1093/annonc/mdw673
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。